Arginine vasopressin serves as one of the most critical neuroendocrine bridges connecting physiological survival mechanisms with complex social cognition and emotional behavior. Synthesized deep within the hypothalamus, this versatile nonapeptide exerts a dual influence across the human organism, functioning peripherally as an indispensable regulator of cardiovascular and renal homeostasis while simultaneously modulating central neural circuits that govern pair bonding, territoriality, stress reactivity, and social memory. Unraveling the multifaceted actions of arginine vasopressin provides essential insights into both evolutionary survival strategies and the neurobiological underpinnings of diverse psychiatric conditions.
Arginine Vasopressin (AVP)
1. Concise Definition
Arginine vasopressin (AVP), historically termed antidiuretic hormone (ADH) or argipressin, is an evolutionary conserved cyclic nonapeptide hormone synthesized primarily by magnocellular and parvocellular neurosecretory neurons in the paraventricular and supraoptic nuclei of the hypothalamus. Structurally composed of nine amino acids linked by an intramolecular disulfide bridge between two cysteine residues, AVP is cleaved from a larger preprohormone precursor and transported axonally to the posterior pituitary for systemic endocrine secretion, as well as distributed centrally throughout diverse limbic and forebrain structures.
In physiological contexts, peripheral AVP functions as the primary hormonal regulator of fluid balance, osmotic equilibrium, and vascular resistance, acting upon distinct G-protein-coupled receptor subtypes situated in the renal collecting ducts and vascular smooth musculature. Within central neurobiology and behavioral neuroscience, AVP serves as a potent neuromodulator and neurotransmitter, orchestrating species-typical social behaviors, selective social affiliation, territorial defense, partner preference, and neuroendocrine responses to physiological and psychological stressors via interaction with the hypothalamic-pituitary-adrenal axis.
2. Etymology & Linguistic Origin
The nomenclature surrounding arginine vasopressin reflects its biochemical composition and early physiological discovery. The term vasopressin is derived from the Latin substantive vas, meaning “vessel” or “duct,” combined with pressio (from premere, “to press” or “to squeeze”), reflecting the peptide’s potent ability to induce vasoconstriction and elevate systemic blood pressure upon its initial isolation. The prefix arginine identifies the specific basic amino acid situated at the eighth position of the nonapeptide chain (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2), which distinguishes mammalian vasopressin from its porcine counterpart (lysine vasopressin or lypressin) and ancestral non-mammalian orthologs such as vasotocin.
Historically, the hormone was independently identified by its renal actions and designated as antidiuretic hormone (from the Greek anti-, meaning “against,” and diouresis, meaning “passage of urine”). As bioanalytical methods elucidated that the pressor and antidiuretic properties belonged to the exact same molecular entity, the biochemical descriptor arginine vasopressin was adopted as the standard nomenclature within biomedical, neuroendocrinological, and psychiatric literature.
3. Pronunciation & Grammatical Form
In standard English academic discourse, arginine vasopressin is pronounced phonetically as /ˌɑːrdʒɪniːn ˌveɪzoʊˈprɛsɪn/ in American English and /ˌɑːdʒɪniːn ˌvæzoʊˈprɛsɪn/ in British English. The abbreviation AVP is pronounced as an initialism: /ˌeɪ viː ˈpiː/.
Grammatically, the term functions as an uncountable proper compound noun. It can appear in attributive noun combinations modifying other technical terms, such as “AVP receptor antagonist,” “AVP-ergic neurotransmission,” or “AVP immunoreactivity.” Derived adjectival forms include vasopressinergic (or AVPergic), denoting neurons, pathways, or pharmacological agents that synthesize, release, or respond specifically to vasopressin.
4. Detailed Conceptual Explanation
The functional architecture of arginine vasopressin operates along two functionally segregated yet intricately coordinated systems: the peripheral endocrine compartment and the central neuromodulatory compartment. In the peripheral compartment, specialized osmoreceptors in the circumventricular organs detect micro-fluctuations in plasma osmolality. When systemic osmolality climbs above physiological set points, or when baroreceptors register critical drops in blood volume or arterial pressure, magnocellular neurons release AVP from the neurohypophysis directly into fenestrated capillaries. Traveling through the systemic circulation, AVP binds to V2 receptors in the basolateral membrane of renal collecting duct epithelial cells, stimulating intracellular cyclic adenosine monophosphate (cAMP) production, the phosphorylation of aquaporin-2 water channels, and their subsequent exocytic translocation to the apical membrane, thereby minimizing free water loss through concentrated urine production.
Simultaneously, central AVP pathways originate from distinct cellular sub-populations, including parvocellular neurons of the paraventricular nucleus (PVN), the bed nucleus of the stria terminalis (BNST), and the medial amygdala. Unlike peripheral secretion, central AVP is released into synaptic junctions and by extrasynaptic volume transmission throughout limbic networks, including the lateral septum, ventral pallidum, central amygdala, and lateral habenula. Centrally acting AVP modulates synaptic plasticity, long-term potentiation, and emotional valencing, conferring adaptive behavioral flexibility in response to social dynamics, threat perception, and environmental instability.
Central AVP signaling exhibits pronounced sexual dimorphism across many mammalian species. The density of vasopressinergic projections originating in the BNST and medial amygdala is typically higher in males, driven by organizational and activational actions of gonadal steroids such as testosterone and dihydrotestosterone. This sexual differentiation mirrors AVP’s distinct role in male-typical behaviors, including scent-marking, territorial mate-guarding, selective aggression against novel conspecifics, and paternal responsiveness. In contrast, while females rely heavily on the closely related nonapeptide oxytocin for maternal nurturing and social buffering, AVP also interacts dynamically with female neuroendocrine circuits to shape affiliative and defensive repertoires.
A critical boundary in understanding AVP lies in the blood-brain barrier. Under physiological conditions, peripheral vasopressin secreted into the bloodstream does not readily cross into cerebral parenchyma, nor does central vasopressin cross freely into systemic circulation in substantial amounts. Thus, peripheral measurements of AVP in serum or plasma do not straightforwardly reflect central vasopressinergic tone or neural release patterns, representing a significant methodological consideration in psychiatric and behavioral research.
5. Historical Development
The foundational discovery of vasopressin began at the end of the nineteenth century. In 1895, British physiologists George Oliver and Edward Albert Schäfer observed that intravenous administration of whole pituitary gland extracts produced an immediate and pronounced rise in mean arterial blood pressure in anesthetized animals. Shortly thereafter, in 1901, Rudolf Magnus and Edward Schäfer demonstrated that pituitary extracts also exerted potent antidiuretic and diuretic effects depending on dosage, paving the way for the functional identification of the posterior lobe’s hormonal factors.
Throughout the early twentieth century, debate persisted regarding whether the pressor and antidiuretic activities were generated by a single hormone or two distinct substances. In 1928, Oliver Kamm and colleagues successfully fractionated posterior pituitary extracts into two chemically distinct preparations: pitressin (vasopressin) and pitocin (oxytocin). The definitive chemical characterization occurred in the 1950s through the groundbreaking work of American biochemist Vincent du Vigneaud. Du Vigneaud isolated, sequenced, and successfully synthesized both oxytocin and arginine vasopressin, an achievement for which he was awarded the Nobel Prize in Chemistry in 1955.
In the late 1960s and 1970s, Dutch pharmacologist David de Wied transformed vasopressin research by demonstrating that posterior pituitary peptides exerted powerful, long-lasting effects on memory consolidation, passive avoidance learning, and adaptive behavior in rodents. De Wied’s “neuropeptide concept” established that AVP was not merely a peripheral endocrine regulator, but an active brain peptide influencing neurocognitive functions. During the 1990s and early 2000s, neuroscientists Thomas Insel, Larry Young, and C. Sue Carter utilized comparative microtine rodent models—contrasting monogamous prairie voles with non-monogamous meadow voles—to reveal that variations in the spatial distribution of vasopressin V1a receptors in reward circuits dictate differences in pair-bonding behavior and social monogamy.
6. Theoretical Foundations
The study of arginine vasopressin intersects multiple prominent theoretical frameworks across evolutionary biology, neuroendocrinology, and psychology. Within evolutionary biology, AVP is understood through the lens of peptide preservation and functional co-option. The ancestral precursor gene duplicated approximately 500 million years ago, diverging into two lineages: the vasopressin-like family and the oxytocin-like family. Evolutionary theory posits that ancient physiological mechanisms dedicated to maintaining cellular osmotic balance were systematically co-opted across vertebrate evolution to regulate social engagement, reproduction, defense of territory, and parental investment, conserving basic survival molecules to orchestrate higher-order social survival.
In behavioral neuroscience, the dual-system framework of social neuropeptides posits that AVP and oxytocin operate in complementary balance. While oxytocin is predominantly conceptualized as facilitating prosocial affiliation, trust, and maternal bonding, AVP is theoretically characterized as the hormone of social vigilance, selective attachment, and boundary defense. Vasopressin links social recognition with defensive motivation, ensuring that social bonds are not indiscriminate, but accompanied by an adaptive wariness or active defense against rival intruders.
Within stress neurobiology, AVP occupies an essential position within the Allostatic Load model developed by Bruce McEwen. Together with corticotropin-releasing hormone (CRH), parvocellular AVP acts synergistically at the anterior pituitary to amplify the secretion of adrenocorticotropic hormone (ACTH), accelerating downstream glucocorticoid release. Under conditions of chronic, unrelenting stress, sustained vasopressinergic hyperactivation contributes to dysregulated allostatic states, predisposing vulnerable individuals to affective, anxiety, and cardiovascular pathologies.
7. Key Components, Types & Dimensions
The biological operations of arginine vasopressin depend on three distinct receptor subtypes, its structural domains, and distinct neuroanatomical distribution networks:
- Arginine Vasopressin Nonapeptide Structure: A nine-amino-acid peptide sequence (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2) containing an essential disulfide bridge linking Cys1 and Cys6, creating a cyclic hexapeptide ring structure coupled to a flexible three-amino-acid C-terminal tail essential for receptor activation.
- V1a Receptor (V1aR / AVPR1A): Coupled to Gq/11 proteins, activating the phospholipase C (PLC) and inositol trisphosphate (IP3) signaling cascade. Abundantly expressed in vascular smooth muscle (mediating vasoconstriction), hepatocytes (glycogenolysis), platelets, and centrally throughout the lateral septum, amygdala, ventral pallidum, and cerebral cortex, where it modulates social recognition, anxiety, territoriality, and pair bonding.
- V1b Receptor (V1bR / AVPR1B / V3R): Also coupled to Gq/11 and PLC cascades; primarily localized in the anterior pituitary corticotrophs, where it synergizes with CRH to trigger ACTH release, and in the hippocampus and amygdala, mediating emotional processing, frustration, and social aggression.
- V2 Receptor (V2R / AVPR2): Coupled to Gs proteins, stimulating adenylyl cyclase and cAMP synthesis. Located almost exclusively in the renal medullary collecting ducts, where it drives the trafficking of aquaporin-2 channels, facilitating free water reabsorption.
- Neuroanatomical Synthetic Centers:
- Magnocellular PVN and SON Neurons: Primary sources of peripheral endocrine AVP released into systemic circulation via the posterior pituitary gland.
- Parvocellular PVN Neurons: Project to the median eminence to control anterior pituitary stress signaling, and project directly to brainstem autonomic nuclei.
- Bed Nucleus of the Stria Terminalis (BNST) and Medial Amygdala: Sexually dimorphic, steroid-sensitive pools sending vasopressinergic fibers across limbic and midbrain targets.
8. Examples & Illustrative Cases
The behavioral actions of AVP are exemplified in the classic prairie vole (Microtus ochrogaster) paradigm. When a male prairie vole mates with a female, central AVP is released within the ventral forebrain. Activation of V1a receptors in the ventral pallidum—an area rich in dopaminergic reward inputs—couples the olfactory signature of the mate with dopamine-driven reinforcement. Consequently, the male forms an enduring partner preference, remaining bonded to the female, assisting in pup rearing, and exhibiting fierce aggression toward unfamiliar females and rival males (selective aggression). In contrast, closely related meadow voles (Microtus pennsylvanicus) have naturally low V1a receptor densities in this region and remain solitary and promiscuous. When researchers artificially elevated V1aR expression in the meadow vole ventral pallidum using viral vector gene transfer, these solitary voles exhibited pair-bonding behavior reminiscent of prairie voles.
In humans, AVP’s subtle influence is evident in social cognitive processing. In controlled laboratory experiments, intranasal administration of AVP to healthy human male volunteers enhances autonomic and facial electromyographic responses to emotionally ambiguous male faces, often biasing neutral or mildly challenging expressions to be perceived as hostile or confrontational. In women, intranasal AVP administration frequently elicits the opposite behavioral effect, promoting affiliative and prosocial responses to female faces. This illustrative discrepancy demonstrates how AVP-driven neural circuits contextualize social stimuli based on sex-specific evolutionary contingencies.
In clinical medicine, the complete absence or functional impairment of peripheral AVP signaling is observed in central diabetes insipidus. Patients lacking AVP secretion due to pituitary trauma, surgical resection, or hypothalamic lesions present with extreme polyuria (excreting up to 15 to 20 liters of dilute urine daily) and unquenchable polydipsia. Administration of desmopressin (DDAVP), a synthetic peptide agonist selective for the V2 receptor, immediately restores renal water reabsorption and halts excessive fluid depletion without causing V1a-mediated hypertension.
9. Measurement & Assessment
Quantifying arginine vasopressin and assessing its central and peripheral actions requires sophisticated bioanalytical and behavioral methodologies:
- Plasma and Serum Immunoassays: Measured via Enzyme-Linked Immunosorbent Assay (ELISA) or Radioimmunoassay (RIA). However, direct measurement of plasma AVP is notoriously difficult because over 90% of circulating AVP is bound to platelets, its half-life is remarkably short (approximately 10 to 24 minutes), and it degrades rapidly at room temperature.
- Copeptin Measurement: Copeptin, the 39-amino-acid C-terminal segment of the prepro-AVP precursor (CT-proAVP), is secreted into systemic circulation in an equimolar ratio with AVP. Copeptin is highly stable in plasma at ambient temperatures and can be quantified rapidly, serving as a reliable surrogate marker for AVP secretion in diagnosing diabetes insipidus, hyponatremia, sepsis, and cardiovascular events.
- Cerebrospinal Fluid (CSF) Analysis: Lumbar or ventricular puncture allows measurement of central AVP concentrations, providing a more direct proxy of central vasopressinergic activity than peripheral blood markers, particularly in studies of neuropsychiatric disorders.
- Genetic Profiling of AVPR1A: Microsatellite repeat polymorphisms in the 5′ flanking promoter region of the human AVPR1A gene (notably the RS3 repeat) are extensively genotyped in behavioral genetics to study individual variations in altruism, pair-bonding quality, empathy, and susceptibility to social disorders.
- Pharmacological Challenge and Neuroimaging: Functional Magnetic Resonance Imaging (fMRI) combined with double-blind, placebo-controlled intranasal AVP administration permits the non-invasive mapping of neural activation patterns in limbic regions (e.g., amygdala, insula, prefrontal cortex) during emotional face processing and social decision-making tasks.
10. Applications & Practical Significance
Arginine vasopressin has wide-ranging applications across acute medicine, clinical pharmacology, psychiatry, and organizational neuroscience. In critical care and emergency medicine, exogenous AVP is employed as a potent vasopressor during septic shock, cardiac arrest resuscitation, and vasodilatory hypotension refractory to norepinephrine. Its non-adrenergic mechanism allows clinicians to elevate systemic vascular resistance and stabilize arterial perfusion pressure while reducing adrenergic overstimulation of the myocardium.
In pharmacology, targeted modifications of the AVP molecule have generated clinically essential therapeutics. Desmopressin (DDAVP), an engineered analogue with minimal V1 activity and prolonged V2 agonism, is standard therapy for central diabetes insipidus, nocturnal enuresis in pediatric patients, and mild hemophilia A and type 1 von Willebrand disease (by inducing endothelial release of coagulation factor VIII and von Willebrand factor). Conversely, non-peptide vasopressin receptor antagonists—termed vaptans (such as tolvaptan and conivaptan)—selectively block V2 or V1a/V2 receptors, serving as effective aquaretic agents for treating euvolemic and hypervolemic hyponatremia in congestive heart failure, liver cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
In neuropsychiatry, vasopressin signaling pathways represent an emerging target for novel pharmacotherapies. Clinical trials have investigated selective V1a receptor antagonists (such as balovaptan) for improving social communication impairments in individuals with autism spectrum disorder (ASD). Other research explores how central AVP pathways mediate trauma consolidation and hyperarousal in post-traumatic stress disorder (PTSD), where heightened vasopressinergic drive may maintain exaggerated autonomic threat reactivity.
11. Research & Empirical Evidence
Substantial empirical research has documented the neurobiological correlates of AVP in social cognition and psychopathology. Landmark studies led by Insel and Young demonstrated that natural variation in the promoter region of the avpr1a gene in voles determined the density and anatomical distribution of V1a receptors in reward centers, directly dictating whether a species exhibited social monogamy or promiscuity. When Donaldson and Young (2008) examined neuropeptide pathways, they affirmed that nonapeptides serve as universal vertebrate evolutionary drivers regulating social attachments, maternal care, and aggressive border defense.
In human clinical genomics, Hasse Walum and colleagues (2008) published an influential study in the Proceedings of the National Academy of Sciences investigating the polymorphic repeat RS3 in the AVPR1A promoter among human twin cohorts. Their empirical findings demonstrated that men carrying the 334 allele scored significantly lower on the Partner Bonding Scale and experienced higher rates of marital discord and self-reported marital crises compared to non-carriers, providing provocative evidence that vasopressinergic variation influences human pair-bonding fidelity and relationship satisfaction.
In autism research, Karen Parker and colleagues (2014, 2018) reported that low cerebrospinal fluid AVP levels in humans and non-human primates strongly correlated with social impairments, and that children with ASD exhibited significantly reduced CSF AVP concentrations compared to neurotypical controls. These findings prompted double-blind randomized clinical trials evaluating intranasal vasopressin, which demonstrated meaningful improvements in social abilities, affect recognition, and communicative behavior among children with ASD.
12. Cultural & Cross-Cultural Considerations
While the biochemical structure and physiological actions of arginine vasopressin are biologically universal across human populations, the behavioral manifestations of vasopressinergic signaling are shaped and filtered through cultural norms, gender role expectations, and social environmental contexts. Because AVP modulates threat vigilance, territorial defense, and social boundary establishment, the behavioral output of vasopressinergic activation depends heavily on culturally learned scripts regarding what constitutes an in-group ally, an out-group threat, or an acceptable aggressive response.
In collectivist cultures, where in-group harmony and out-group demarcation are pronounced, the cognitive salience of vasopressinergic vigilance may align with cultural mandates prioritizing collective defense, family duty, and selective loyalty. In individualistic cultural contexts, vasopressinergic influences may manifest more predominantly through interpersonal boundary setting, partner jealousy, and competitive achievement. Cross-cultural bio-behavioral research highlights the necessity of avoiding simplistic biological determinism; neuropeptides like AVP act as biological amplificators of contextual social salience rather than rigid determinants of static cultural behaviors.
13. Criticisms, Debates & Limitations
Despite significant empirical advancements, vasopressin research remains surrounded by several methodological debates, conceptual controversies, and pharmacological limitations:
- The Intranasal Delivery Controversy: A major scientific debate centers on the exact mechanism through which intranasally administered AVP reaches the human brain. While proponents argue that peptide molecules travel via olfactory and trigeminal nerve bundles directly into the CSF, bypassing the blood-brain barrier, critics maintain that much of the intranasal dose enters the peripheral circulation, potentially producing systemic cardiovascular effects that indirectly alter brain state and behavior through secondary autonomic feedback.
- Simplistic Behavioral Dichotomies: Early popular science narratives frequently reduced oxytocin to the “love hormone” and vasopressin to the “aggression or male hormone.” Contemporary neuroscientists criticize this dichotomy as inaccurate, noting that AVP plays crucial prosocial and affiliative roles, oxytocin facilitates out-group hostility and defensive aggression, and both peptides cross-react with each other’s receptors at pharmacological doses.
- Replication Difficulties in Human Neuropeptide Trials: Several high-profile trials investigating AVP analogues and antagonists in psychiatric populations have yielded mixed results. For example, large-scale Phase II/III clinical trials evaluating the V1a antagonist balovaptan for ASD failed to consistently replicate earlier behavioral improvements across primary endpoints, leading to regulatory and developmental re-evaluations.
- Peripheral vs. Central Non-Equivalence: Many published studies continue to draw inferences regarding central emotional states from peripheral plasma or serum AVP concentrations. Because systemic vasopressin release is primarily dictated by fluid osmolality, posture, and autonomic status, inferring complex mental or psychiatric traits from peripheral venipuncture remains a major methodological limitation in affective neuroscience.
14. Related Terms & Distinctions
Understanding AVP requires distinguishing it from closely related molecules, biological concepts, and functional analogues:
- Oxytocin (OXT): A sister nonapeptide differing from AVP by only two amino acids (leucine instead of arginine at position 8, and isoleucine instead of phenylalanine at position 3). While AVP focuses predominantly on vigilance, fluid retention, and selective mate defense, oxytocin specializes in parturition, milk ejection, prosocial buffering, and generalized social bonding.
- Vasotocin (AVT): The ancestral non-mammalian ortholog found in birds, reptiles, amphibians, and fish, which combines structural and functional properties of both mammalian vasopressin and oxytocin.
- Desmopressin (DDAVP): A synthetic pharmacological analogue of vasopressin engineered with deamination at position 1 and D-arginine at position 8. It exhibits 2,000 to 4,000 times lower vasoconstrictive (V1) activity while preserving potent renal antidiuretic (V2) activity with a substantially longer plasma half-life.
- Corticotropin-Releasing Hormone (CRH): A hypothalamic peptide that cooperates synergistically with parvocellular AVP at the level of the anterior pituitary gland to stimulate ACTH release and orchestrate endocrine stress reactivity.
- Copeptin (CT-proAVP): The C-terminal glycoprotein cleavage product of the prepro-vasopressin precursor molecule, utilized in clinical medicine as a stable, equimolar diagnostic proxy for systemic AVP secretion.
15. Summary & Key Takeaways
Arginine vasopressin represents a remarkable evolutionary achievement in biological design, harmonizing the preservation of fluid balance with the execution of nuanced social behaviors essential for survival. As an endocrine hormone, it preserves vascular perfusion and concentrates urine through renal aquaporin channels. As a central neuropeptide, it acts through V1a and V1b receptors to shape pair bonding, social memory, defensive vigilance, and neuroendocrine stress reactivity.
From the early physiological isolations of Oliver, Schäfer, and du Vigneaud to modern translational investigations in autism, psychiatric genetics, and critical care medicine, AVP continues to reveal the profound interconnectedness of autonomic survival and social affiliation. Future advancements in targeted receptor pharmacology, optogenetics, and direct central biomarker profiling promise to further illuminate how this primordial molecule shapes the human mind and body.
In conclusion, arginine vasopressin exemplifies the intricate reciprocity between physiological homeostasis and emotional adaptation. Far from being a mere fluid-retaining agent, AVP is an ancient architect of vertebrate sociality, transforming basic cellular survival drives into the enduring bonds, defensive instincts, and behavioral adaptations that sustain life across diverse ecological niches.
References
- Donaldson, Z. R., & Young, L. J. (2008). Oxytocin and vasopressin rare social behaviors: Exploring the neurobiology of pair bonding. Science, 322(5903), 900–904. https://doi.org/10.1126/science.1158668
- du Vigneaud, V., Ressler, C., Swan, J. M., Roberts, C. W., Katsoyannis, P. G., & Gordon, S. (1953). The synthesis of an octapeptide amide with the hormonal activity of oxytocin. Journal of the American Chemical Society, 75(19), 4879–4880. https://doi.org/10.1021/ja01115a553
- Insel, T. R., & Shapiro, L. E. (1992). Oxytocin receptor distribution reflects social organization in monogamous and nonmonogamous voles. Proceedings of the National Academy of Sciences, 89(13), 5981–5985. https://doi.org/10.1073/pnas.89.13.5981
- Parker, K. J., Garner, J. P., Libove, R. A., Hyde, S. A., Hornbeak, K. B., Carson, D. S., Liao, C.-P., Phillips, J. M., Hallmayer, J. F., & Hardan, A. Y. (2014). Plasma vasopressin concentrations are associated with social impairment in children with autism spectrum disorder. Biological Psychiatry, 76(9), 740–747. https://doi.org/10.1016/j.biopsych.2014.02.008
- Walum, H., Westberg, L., Henningsson, S., Neiderhiser, J. M., Reiss, D., Igl, W., Ganiban, J. M., Spotts, E. L., Pedersen, N. L., Eriksson, E., & Lichtenstein, P. (2008). Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proceedings of the National Academy of Sciences, 105(37), 14153–14156. https://doi.org/10.1073/pnas.0803081105